Opportunities to Participate in Clinical Research

The goal of the Restoring Insulin Secretion (RISE) Study is to find new approaches to prevent or treat types 2 diabetes. We’re looking for adults who were recently diagnosed with diabetes or who are at risk for diabetes.

Click here to learn more about this study conducted by the Diabetes Research Group at the University of Washington.

GRADE will determine which combination of two medications is best for glycemic control, has the fewest side effects, and is the most beneficial for overall health.

Click here to learn more about this study conducted by the Diabetes Research Group at the University of Washington.

BRIDge is a research study to facilitate the understanding of diabetes and immune-mediated diseases. The study consists of a computer registry where we store your contact, research, and health information, and a sample repository where we keep blood samples for current and future use in our research. The samples will be used for many different studies.

An important part of this study is the sharing of information between researchers of different immune-mediated diseases. The samples and information obtained in this study are part of Benaroya Research Institute’s Immune-Mediated Diseases Registry and Repository.

We may contact you to see if you will come in for additional study visits or to update your health and contact information. We will always tell you what we need and let you decide if you are able to help us at that time. We may also contact you to let you know that you may be eligible for other studies.

Type of participant we are looking for:
Individuals diagnosed with type 1 diabetes within the last ten years.

Clinicaltrials.gov number

None

Who to contact:
Nancy Wickstrom
Phone number: 1-800-888-4187
Email address: diabetes@BenaroyaResearch.org

Website for more details about the study:
https://www.benaroyaresearch.org/our-research/diabetes-clinical-research/find-study/bridge-study-of-t1d

This study tests Abatacept in persons who’ve been determined to be at risk, but not yet diagnosed, to see if it can help delay or prevent the onset of type 1 diabetes. Abatacept is a medication that has shown promise in preserving insulin production in people newly diagnosed with type 1 diabetes. The current study is testing whether Abatacept can help preserve insulin production and delay or prevent the onset of type 1 diabetes in people who are at high risk of developing the disease over the next five years.

Type of participant we are looking for:

  • Participation in TrialNet’s Pathway to Prevention Study, and thus, a relative of an individual with type 1 diabetes<
  • Ages 6 to 45
  • Normal glucose tolerance
  • Two or more diabetes-related autoantibodies

Clinicaltrials.gov number

NCT01773707

Who to contact:
Nancy Wickstrom
Phone number: 1-800-888-4187
Email address: diabetes@BenaroyaResearch.org

Website for more details about the study:
https://www.diabetestrialnet.org/abatacept/

TrialNet offers this study at various locations throughout the U.S., including Benaroya Research Institute in Seattle. TrialNet is an international network dedicated to the study, prevention and early treatment of type 1 diabetes. TrialNet sites are located throughout the United States, Canada, Finland, United Kingdom, Italy, Australia and New Zealand.

TrialNet’s Pathway to Prevention studies the development of type 1 diabetes, and screens relatives of people with type 1 diabetes for their risk of developing the disease. Relatives of people with type 1 diabetes have about a 3 to 4 percent chance of being positive for the antibodies associated with diabetes. The Natural History Study is conducted in two parts:

  • Screening
  • Monitoring

This is the screening part of the study, in which a simple blood test is done to screen for the presence of diabetes-related antibodies. If antibodies are confirmed to be present, participants will be invited to join the monitoring part of the study and have additional testing. People who are found to be at moderate to high risk of developing type 1 diabetes may be eligible to participate in a prevention trial.

TrialNet offers this study at many locations throughout the U.S. and internationally, including Benaroya Research Institute in Seattle. TrialNet is an international network dedicated to the study, prevention and early treatment of type 1 diabetes.

Type of participant we are looking for:

  • Individuals 1 through 45 years old who have an immediate family member with type 1 diabetes (such as a child, parent, or sibling)
  • Individuals 1 through 20 years old who have an extended family member with type 1 diabetes (such as a cousin, niece, nephew, aunt, uncle, grandparent, or half-sibling)

Clinicaltrials.gov number

NCT00097292

Who to contact:
Nancy Wickstrom
Phone number: 1-800-888-4187
Email address: diabetes@BenaroyaResearch.org

Website for more details about the study:
https://www.diabetestrialnet.org/PathwayToPrevention/index.htm

This study tests whether Tocilizumab can help preserve or delay destruction of remaining beta cells in people recently diagnosed with type 1 diabetes, and extend the ability to naturally produce insulin.

Maintaining beta cell function has numerous benefits, better blood glucose control, decreased complications, and decreased hypoglycemia.

Type of participant we are looking for:

  • Ages 6 to 45
  • Have been diagnosed with type 1 diabetes within the last 2 ½ months

Clinicaltrials.gov number

NCT02293837

Who to contact:
Nancy Wickstrom
Phone number: 1-800-888-4187
Email address: diabetes@BenaroyaResearch.org

Website for more details about the study:
http://www.extendstudy.org/eligibility#.WIYqFH3r140

EXTEND is being conducted by the Immune Tolerance Network and TrialNet and is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (NIH funded).